Rate My Professor Iain Abbott

Dr. Iain Abbott is a Senior Research Fellow in the Department of Infectious Diseases within the School of Translational Medicine, Faculty of Medicine, Monash University. He serves as a Clinical Microbiologist and Infectious Diseases Physician at Alfred Health. Qualified with MBBS, FRACP, and FRCPA credentials, Abbott is pursuing a PhD focused on antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) in-vitro modelling. His research addresses antimicrobial resistance (AMR), with a particular emphasis on urinary tract infections (UTIs), which affect over 400 million people annually worldwide. Leading the Abbott Group, he develops clinically relevant PK/PD models, including a unique dynamic bladder infection model, to optimize antimicrobial dosing, evaluate resistance emergence, and support novel drug development. Abbott heads the Infection and Microbiome theme for the Monash University Bladder and Kidney Health Discovery Program and directs the iOASIS research program targeting superbug infections.

Abbott's career includes serving as an Infectious Diseases Physician at Alfred Hospital since 2017 and as a Lecturer in the Faculty of Medicine at Monash University from 2011 to 2016. He has secured major grants, including an NHMRC EL-1 Investigator Grant (2025–2029) for innovating UTI diagnostics, treatment, and prevention; a U.S. FDA contract (2023–2026) for bridging UTI PK/PD models to clinical breakpoints and drug development; and the JPIAMR PHASEK project (2025–2028) on phage-antimicrobial synergy against MDR Escherichia coli and Klebsiella pneumoniae. Notable awards include the ASA Research Grant (2022), Bladder and Kidney Health Discovery Program Seed Funding Grant (2023), ISAP Young Investigator Award (2018), and ESCMID Travel Award (2016). Key publications encompass 'Antibiotic management of urinary tract infections in the post-antibiotic era: a narrative review highlighting diagnostic and antimicrobial stewardship' (2023), 'Nocardia species distribution and antimicrobial susceptibility within Australia' (2024), 'Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model' (2025), and 'Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions' (2025). Abbott holds leadership roles such as Vice-President of the Australian Society for Antimicrobials (2023–present), Chair of the Australian Committee for Antimicrobial Susceptibility Testing (2023–present), Scientific Editor of the ASA Newsletter (2021–present), ESCMID Local Champion for Australia (2025–present), and member of the European Study Group for Urinary Tract Infections (2025–present). His work influences antimicrobial guidelines, health policy, and clinical practice through committee contributions and public engagement, including a radio interview on AMR.